Literature DB >> 18156574

Early-life pulmonary arterial hypertension with subsequent development of diffuse pulmonary arteriovenous malformations in hereditary haemorrhagic telangiectasia type 1.

C J Mache1, A Gamillscheg, H H Popper, S G Haworth.   

Abstract

The case history is presented of a male infant who was thought to have idiopathic pulmonary arterial hypertension (PAH) at 3 months of age. Subsequently the PAH decreased unexpectedly and diffuse pulmonary arteriovenous malformations (PAVMs) were seen at 6.9 years of age for the first time. Hereditary haemorrhagic telangiectasia type 1 (HHT1) related to an endoglin mutation was diagnosed. At 10.3 years of age a lung biopsy showed diffuse PAVMs as well as pulmonary arteriopathy with medial hypertrophy. This is the first case of HHT1 presenting with PAH at such a young age. The subsequent decrease in pulmonary arterial pressure (PAP) was probably caused by the development of PAVMs. In the presence of PAVMs, measurement of the PAP may underestimate the extent of PAH-related vasculopathy.

Entities:  

Mesh:

Year:  2008        PMID: 18156574     DOI: 10.1136/thx.2007.076109

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  13 in total

1.  Altered MicroRNA processing in heritable pulmonary arterial hypertension: an important role for Smad-8.

Authors:  Kylie M Drake; Deborah Zygmunt; Lori Mavrakis; Phyllis Harbor; Lingli Wang; Suzy A Comhair; Serpil C Erzurum; Micheala A Aldred
Journal:  Am J Respir Crit Care Med       Date:  2011-09-15       Impact factor: 21.405

2.  Pulmonary hypertension in hereditary haemorrhagic telangiectasia.

Authors:  Veronique Mm Vorselaars; Sebastiaan Velthuis; Repke J Snijder; Jan Albert Vos; Johannes J Mager; Martijn C Post
Journal:  World J Cardiol       Date:  2015-05-26

Review 3.  Cardiac and Hemodynamic Manifestations of Hereditary Hemorrhagic Telangiectasia.

Authors:  Ahmed Farhan; Muhammad A Latif; Anum Minhas; Clifford R Weiss
Journal:  Int J Angiol       Date:  2022-07-09

Review 4.  Genetics and genomics of pulmonary arterial hypertension.

Authors:  Rajiv D Machado; Oliver Eickelberg; C Gregory Elliott; Mark W Geraci; Masayuki Hanaoka; James E Loyd; John H Newman; John A Phillips; Florent Soubrier; Richard C Trembath; Wendy K Chung
Journal:  J Am Coll Cardiol       Date:  2009-06-30       Impact factor: 24.094

5.  Hemodynamic and genetic analysis in children with idiopathic, heritable, and congenital heart disease associated pulmonary arterial hypertension.

Authors:  Nicole Pfarr; Christine Fischer; Nicola Ehlken; Tabea Becker-Grünig; Vanesa López-González; Matthias Gorenflo; Alfred Hager; Katrin Hinderhofer; Oliver Miera; Christian Nagel; Dietmar Schranz; Ekkehard Grünig
Journal:  Respir Res       Date:  2013-01-09

Review 6.  Pulmonary Arterial Hypertension: A Current Perspective on Established and Emerging Molecular Genetic Defects.

Authors:  Rajiv D Machado; Laura Southgate; Christina A Eichstaedt; Micheala A Aldred; Eric D Austin; D Hunter Best; Wendy K Chung; Nicola Benjamin; C Gregory Elliott; Mélanie Eyries; Christine Fischer; Stefan Gräf; Katrin Hinderhofer; Marc Humbert; Steven B Keiles; James E Loyd; Nicholas W Morrell; John H Newman; Florent Soubrier; Richard C Trembath; Rebecca Rodríguez Viales; Ekkehard Grünig
Journal:  Hum Mutat       Date:  2015-10-12       Impact factor: 4.878

7.  Correction of nonsense BMPR2 and SMAD9 mutations by ataluren in pulmonary arterial hypertension.

Authors:  Kylie M Drake; Benjamin J Dunmore; Lauren N McNelly; Nicholas W Morrell; Micheala A Aldred
Journal:  Am J Respir Cell Mol Biol       Date:  2013-09       Impact factor: 6.914

Review 8.  Metabolism in Pulmonary Hypertension.

Authors:  Weiling Xu; Allison J Janocha; Serpil C Erzurum
Journal:  Annu Rev Physiol       Date:  2021-02-10       Impact factor: 19.318

9.  Oxidative stress contributes to endothelial dysfunction in mouse models of hereditary hemorrhagic telangiectasia.

Authors:  Mirjana Jerkic; Valentin Sotov; Michelle Letarte
Journal:  Oxid Med Cell Longev       Date:  2012-12-25       Impact factor: 6.543

Review 10.  Endoglin: a critical mediator of cardiovascular health.

Authors:  Navin K Kapur; Kevin J Morine; Michelle Letarte
Journal:  Vasc Health Risk Manag       Date:  2013-05-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.